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Mia Brinkley 
Insulin: Roles and Functions in Biochemistry and U.S. Healthcare 
There is a long list of drugs that treat conditions affecting a large population of the U.S. 
today. Genetic predisposition, individual lifestyle, and environmental factors all influence many 
of the most prominent diseases in our population, and the development of drugs as a treatment 
strategy has brought about both burdens and benefits for the patient. One example of one of these 
drugs is insulin, with 30% of Diabetes patients using insulin.1 Today, over 8.3 million people are 
prescribed insulin, and that number is expected to grow substantially over time.1 This massive 
market is controlled by a small number of manufacturers, causing high cost of insulin and low 
accessibility for patients. While a higher percentage of the U.S. population has Type 2 Diabetes 
than Type 1, I will be focusing on Type 1 because of its more limited range of treatment options. 
Type 1 Diabetes occurs in over 30 million Americans.1 It is caused by an autoimmune 
process in which CD8 positive cytotoxic T cells recognize beta-cell autoantigens by recognizing 
MHC class I peptide complexes. This produces a chronic inflammatory response to eliminate 
insulin-producing beta cells, causing insulin deficiency and hyperglycemia.2 In previous studies, 
glutamic acid decarboxylase (GAD) and ICA 512 protein tyrosine phosphatase (in 60-85% of 
patients) have been found to 
help in elimination of insulin.2 
Insulin is naturally 
produced by the body, secreted 
by pancreatic beta-cell in the 
Islets of Langerhans as a 51-
residue protein.3 This release 
 
Figure 1. Insulin leaves β-cells of pancreatic Isles of Langerhans 
when stimulated. Pipeline includes the pancreas, an Islet of 
Langerhans surrounded by acinar cells, and β-cell that is stimulated to 
produce and release insulin. Image created using BioRender. 
is pictured in Figure 1, showing the 
release of insulin from pancreatic β-
cells. The initial protein, proinsulin, 
has an A and B chain connected by 
disulfide bonds, as shown in the 
Figure 2, which is post-translationally 
modified to form mature insulin.3 
Insulin contains three alpha helices: A1-
A8, A12-A18, and B9-B19, containing 
one intra and two interchain disulfide bonds4 (Figure 3). 
Insulin works by binding to the insulin receptor (IR), a homodimer with two alpha 
subunits, each at 135 kDa; two beta subunits, 
each at 95 kDa; and two minor glycoprotein 
(gamma) subunits, each at 210 kDa.5 The 
alpha subunit works to bind insulin, and the 
beta subunit consists of a tyrosine kinase that 
phosphorylates itself at a phosphotyrosine, 
phosphoserine, and phosphothreonine (Figure 
4). The gamma subunit is the transmembrane 
portion, extending through the plasma 
membrane to connect to the inside of the cell. 
 
Figure 2. Animation of insulin molecule.3 
 
Figure 3. Structure of insulin molecule. Alpha 
and beta chains are colored orange and teal, 
respectively, with intra and inter-disulfide bonds 
labeled with stars. 
 
plasamembrane to connect to the inside of the cell. 
 
Figure 4. A) Overview of tyrosine kinase subunit of insulin receptor protein. Tyrosine kinase is colored 
cyan, the swinging loop region is colored magenta, the two Mg2+ coenzymes are colored red, and 
multicolored is an ATP analogue, with carbon green, nitrogen blue, oxygen red, and sulfur orange. 
 
Figure 5. Tyrosine kinase undergoes transitional change upon ATP binding. A) Inactivated tyrosine 
kinase region of insulin receptor protein. Highlighted in magenta is part of the loop that swings during 





When insulin binds to one of the receptor’s alpha subunit, it causes a shape change that is 
propagated into the intracellular region and activates the tyrosine kinases.6 The transition from 
the inactive to the active state is shown in Figure 5. The active site binds to ATP, which it uses 
to phophorylate its targets. The transition between the inactive and active state is characterized 
by several tyrosines being phosphorylated, causing a loop portion to swing out of the active site 
and allow ATP and magnesium entry for enzymatic process.6 
All of this information that’s known about the insulin protein and insulin receptor is 
helpful to researchers to maximize efficiency of Diabetes drugs today, but this information has 
not been known nearly as long as Diabetes has been around. Treatments to Type 1 Diabetes, 
prior to the use of insulin as a drug, were trying and physically exhausting. Developed in the 
early 20th century, starvation therapy was a way to keep sugar below tolerance levels, measured 
routinely in urine. This would hopefully prevent organ failure, but it meant that a patient had to 
restrict themselves to 800 calories per day.7 This caused weakness and low resistance to 
infections, as well as a generally decreased quality of life. Without treatment, diabetes would 
start with weight loss, listlessness, hunger, and thirst, as ketones clog organs and the kidneys 
begin to fail. Eventually, coma and then death would ensue. Treatments were becoming more 
and more important as the 20th century brought cleaner water and better sewage. As child 
mortality rates declines, the rates of Type 1 Diabetes increased with the growing population. 
Type 2 also increased, as being larger was a sign of wealth and prosperity. A better treatment 
was imperative. 
However, it wasn’t for lack of trying that the treatment development was slow. Since 
1869, when Paul Langerhans identified insulin-secreting pancreatic cells that floated in clusters 
of acinar cells—these clusters called islets of Langerhans—there was work on cats, dogs, guinea 
pigs, and rabbits to find pancreatic extract for treating patients.7 One group in 1912 thought that 
bacterium in milk would cleanse the alimentary canal from excess sugar. Patients were, of 
course, told to drink more milk, not knowing of the sugar contained in what they were drinking. 
In 1915, J.D. Rockefeller founded a medical research institute, let by Israel Kleiner, to work on 
pancreatic extracts. Kleiner’s method was to grind up dog pancreases, put them in solution with 
salt, and inject them into the now-diabetic dogs. He found 50% decline in blood sugar levels, but 
the negative side effects prevented further investigation.7  
The world-changing science was in 1914, when a group of scientists at University of 
Toronto banded together to find a way to extract insulin (Figure 6). The team was led by J.J.R. 
Macleod and included F.G. Banting, C.H. Best, J.B. Collin, J.Hepburn, J.K. Latchford, and E. 
Clark Noble. They used rabbits and developed manufactured pancreatic extract, first calling it 
“isletin.” At first 






results, it was 
later successfully 
given as an injection to Leonard Thompson, a 14-year old patient of Toronto General Hospital.8 
The Toronto group, on January 25, 1922, settled an agreement with Connaught Anti-Toxin 
Laboratories for the manufacturing of this extract, but the production failed by March. Collin and 
 
Figure 6. Cover of Toronto Daily Star, published on March 22, 1922, showing the 
four doctors leading the insulin treatment research. 
Best succeeded in regaining the formula in May. By May 3rd, the extract was successfully 
extracted from cow pancreas and was first referred to as insulin by Macleod. Elizabeth Hughes 
Gossett, daughter of U.S. statesman Charles Evans Hughes, was the famous recipient of the first 
insulin treatment for Type 1 diabetes, receiving over 42,000 shots from age 12 until her death.7 
Banting refused to put the patent for insulin in his name, believing it would be unethical 
for a doctor to benefit from the discovery of a life-saving treatment; Collin and Best respected 
this decision and agreed to sell the patent for insulin for $1 to the University of Toronto. The 
intention was to provide the quickest availability to the public and allow anyone to prepare the 
extract with no profitable monopoly to develop.9 While this was meant to prevent monopolizing 
on the drug production and distribution, it did little in the end for the benefits of patients. The 
University formed the Diabetic Clinic in Toronto General Hospital in June of 1922 and 
established the Insulin Committee in August to control licensing, patenting, and trademarking of 
the new drug.8 The teamed with Eli Lilly to allow it to take out any U.S. patents “for 
manufacturing improvements, but the university would receive the patent right for the rest of the 
world, and they let other companies around the world receive the patent from the University.9 By 
May of 1923, insulin was made commercially available in Great Britain, and by June, the initial 
agreement with Eli Lilly ended, allowing other pharmaceutical companies to apply for licenses 
for distribution. By October of 1923, insulin was made commercially available in the U.S. and 
Canada. The Nobel Prize in Physiology or Medicine was given to Banting and Macleod that 
same month, for their discovery of insulin.10 
Over the next three years, production was massive. The world began hearing of the new 
drug to treat Diabetes, and what rose was a new hope in patients for a normal way of life. By 
1926, insulin was patented or trademarked in 44 countries world-wide. Through the next 100 
years, continual work was done to maximize its productivity in the body. At Novo Nordisk, one 
the of three companies controlling the insulin market today, Hans Christian Hagedorn added 
protamine to the drug to alter its absorption and prolong its duration of action. This was not able 
to mix with fast-acting insulin, so he added zinc to the drug and formed neutral protamine 
Hagedorn (NPH). This allowed a single daily injection for many patients and was patented in 
1946.9 Slow-acting insulins were introduced in the 1950s to extend patents into the 70s, then 
introduced monocomponent insulins and single-peak insulins—by Novo Nordisk and Eli Lilly, 
respectively—which extended patents into the 80s.  
Genentech, a small start-up biotechnology firm with no income and limited resources, 
was the first to synthesize and patent human insulin the 1970s.11 They incorporated the gene for 
insulin into E. coli—a process called DNA recombination—to harvest the protein from bacterial 
fermentation. Human insulin was the first protein to be FDA-approved for treatment using this 
method (Figure 7).12 This was only accomplished only a couple years before DNA 
recombination and purification was first done and published. With a royalty agreement with Eli 
Lilly, human insulin hit the 
market as Humulin R in 19829 
and instigated a surge in 
investment in biotechnology. And 
it worked better for patients.  
Only six years later, 
Nordisk brought its first human 
insulin to market, using 
biochemical methods to convert Figure 7. Illustration of the recombination process to produce 
isolated human insulin.12 
bovine insulin to human insulin.9 Not long after, Sanofi did the same, and human insulin would 
determine the three companies to own the entire insulin market for the following forty years. 
Today, insulin treatment is much more than a single-type injection that is the same for 
every patient. In 1977, human insulin was synthetically manufactured from recombinant DNA 
and replaced beef and pork insulin.13 Today, insulin analogs are replacing human insulin because 
they are less likely to clump together in high concentrations under the skin, causing slow and 
unpredictable absorption from subcutaneous tissue the way human insulin does. Analogs have a 
more predictable duration of action, and work quicker, last longer, and have a less peak-like 
effect. As of 2010, only 15% of the insulin market uses human insulin, while 92% use analog 
insulin.14  
There are three types of insulin. Fast-acting insulin, as the name suggests, is absorbed 
quickly from subcutaneous tissue into the bloodstream and is used during meals to regulate blood 
sugar levels.13 These include rapid-acting insulin analogs—such as Insulin Aspart, Lyspro, and 
Glulisine—with an onset time of 5-15 minutes, a peak effect of 1-2 hours, and an overall 
duration of 4-6 hours. There is also regular human insulin, with an onset time of 30 minutes-1 
hour, a peak effect of 2-4 hours, and a duration of 6-8 hours. Another type is intermediate-acting 
insulin, which absorbs slower and lasts longer. This is used overnight, while fasting, and between 
meals. It includes NPH human insulin, with an onset of 1-2 hours, a peak effect of 4-6 hours, and 
a duration over 12 hours; and premixed insulin, a mixture of NPH and regular human insulin of 
rapid-acting analog. This gives a combination of short and intermediate-acting insulins. The third 
type is long-acting insulin, which is absorbed slowly, has minimal peak effect, and a stable 
plateau over most of the day. This is used overnight, while fasting, and between meals, and it 
mainly consists of long-acting insulin analogs—such as Insulin Glargine and Detemir—with an 
onset of 1.5-2 hours, when the effect plateaus then holds a flat duration of action of 12-24 
hours.13 Figure 8 visualizes these effects. 
 Most patients with Type 1 Diabetes must take basal insulin throughout the day, which 
controls insulin levels between meals, as well as mealtime insulin to control those levels during 
meals, when glucose intake spikes.14 
A typical day consists of one or two 
injections of long-acting, and rapid-
acting for every meal. Type 2 
patients may only need long-acting 
insulin injections. Most patients still 
use syringes as the delivery method. 
While insulin pens combine the vial 
and syringe, being safer and more 
convenient, they are used less because of higher cost. CSII devices—Continuous subcutaneous 
insulin infusion devices—are battery-powered, computerized, and deliver short-acting insulin 
under the skin continuously throughout the day via an abdominal catheter. These are also 
expensive but can last years and are commonly used. Another delivery method is infusion, using 
a direct IV, but this is reserved for patients when in a hospital. A new method is inhaled insulin, 
which is rapid-acting and meant to be used before meals, in combination with long-acting 
insulin.  
 There are other medications to treat insulin today that are not insulin, called oral 
antidiabetic drugs (OADs). One is Metformin, a treatment for Type 2 Diabetes that most 
commonly works in conjunction with insulin. It has been used since the 1950s, only briefly taken 
 
Figure 8. Activity profiles of different types of insulin on the 
market today.13 
off the market due to concerns of lactic acidosis, and acts by blocking a mitochondrial redox 
shuttle to inhibit gluconeogenesis in the liver.15 Another class of drugs are glucagon-like peptide 
1 (GLP-1) receptors, which also work in Type 2 Diabetes patients to increase insulin secretion in 
response to oral and intravenous glucose.16 Another common medication includes sodium 
glucose co-transporter 2 (SGLT-2) inhibitors. These work in combination with insulin for Type 1 
and Type 2 Diabetes. SGLT-2 inhibitors block the reabsorption of glucose by the kidney and 
reducing blood glucose levels as glucose is excreted from the body.17 While these classes of 
drugs provide promising progress toward helping those with Diabetes, they are commonly only 
given to Type 2 patients and almost always still work in conjunction with insulin. Making OADs 
more accessible to Type 2 users is a worthwhile endeavor, but the significant problem still 
remains of providing all DM affordable access to the still most-widely used medications, insulin. 
 Over 8.3 million people in the U.S. require insulin. And the worldwide market is 
expected to increase by at least 20% by 2030.14 To begin with the problems of the insulin 
market, there is limited competition for three major reasons. Insulin products are not 
interchangeable, there are currently only three insulin manufacturers in the U.S. market, and 
there have been no regulations to allow biosimilar products to form a generic insulin. 
 The cost of insulin today is outrageous. From 2002 to 2016, the price of insulin has 
increased by 218%.18 The last four years of that period, the increase was 450% above general 
inflation. Estimated cost of spending, per patient, has increased from $231.48 in 2002 to $736.09 
in 2013.19 And the average price of insulin has increased from $4.34 to $12.92 per milliliter from 
2002 to 2013. These are partially due to continually newer and “better” insulin products coming 
to market, raising the cost and patents, but these increasing costs are discouraging patients from 
wanting to switch to newer insulin when they do work better. Many patients are afraid of not 
being able to pay their medical bills or of losing their health insurance altogether.  
 While the high cost of insulin is not new or that surprising, it affects millions of 
Americans each year. In a 2019 Yale study, 25.5% of insulin users reported cost-related insulin 
underuse.20 This is both dangerous and unacceptable, and highlights “an urgent need to address 
affordability of insulin.”  
 Because of non-interchangeable insulin products, there is little competition in the insulin 
market. There are large differences in insulin types, so patients cannot easily change them.14 
With this, there is little autonomy in patient decisions on what form of insulin is best for them, 
and changing forms is left for the provider to decide. 
The three insulin manufacturers are Eli Lilly, Novo Nordisk, and Sanofi, representing 
over 90% of the global insulin market.14 While each of these companies have multiple types, 
Novo Nordisk have a monopoly on ultra-long acting insulin. This is because of patents. Patents 
last 20 years, and companies can receive a new patent every time they improve the way to 
produce or administer the drug, or with changes in duration or onset time. For insulin 
specifically, this can be for using new, non-active ingredients, changing the manufacturing 
processes, or developments in administration devices. Patents have followed the development of 
insulin through time, starting with animal insulin in 1923, the first human insulin in 1982, and 
new analog patents from 1996-2005.14 When a new product comes to market, older products are 
less prescribed and often discontinued from the manufacturer. This prevents patients from having 
access to off-patent insulins, which would potentially be cheaper. If one looks at the minor 
changes in insulin from 1996 to 2005, the price increase of the newly-patented insulin is often 
not balanced by equally-improved effects. For example, analogue insulin has shown improved 
effects compared to human insulin, as discussed earlier, but the estimated expenditure per patient 
in 2013 was $228.20 for human insulin and $507.89 for analog, making it significantly less 
affordable.19 
To complicate things, insulin has been considered a drug rather than a biological drug or 
biologic. This designation does not allow generic versions to be made when the patent expires. 
As of 2009, however, the FDA created a legal path for biosimilars to reach the market, called the 
Biologics Price Competition and Innovation Act.21 This changed the designation from a drug to a 
biological product. Other companies can now create biosimilar product—where they would 
previously be called generics—where the molecular and biological structure doesn’t show any 
clinically meaningful difference from the biologic. This provision took effect on March 23, 2020, 
and is predicted to lower the cost of insulin as other companies produce these biosimilars.  
This transition of insulin’s designation should not be discounted. Generics are an 
enormous market in the drug industry. Over 80% of prescriptions are for generic drugs; this 
saves health care systems billions of dollars each year and are critical for payers and patients.9 
And yet, there is some skepticism in the savior mentality of producing generics to fix the insulin 
price. With this Act, insulin companies are still allowed the usual patents of 20 years when they 
introduce “improvements,” and with such a large molecule, there is a large number of possible 
incremental changes. This is the process has been continuing since insulin first came to market 
and is referred to as “evergreening.” Developing a biosimilar is incredibly challenging, as 
biologics are huge molecules compared to drugs. Creating biosimilars take about twenty-two 
times the cost of creating a small-chemical molecule drug, and this expense will slow 
competitors and possibly prevent any price drops.14 It is incredibly difficult to prove that two 
molecules are structurally identical, which is necessary for a generic. There is also a more 
extensive approval process that will slow progress and add expenses. This is the case in Europe: 
recently, they have introduced generic insulin, but the price reductions were 20-40% instead of 
the usual 80% for introduction of a generic.9 
A study done by The Commonwealth Fund suggests a different tactic in increasing 
affordability: Increase both the access to insurance coverage and the generosity of that coverage 
for insulin patients.1 Reporting that as many as ¼ of insulin patients report rationing insulin to 
save money, policies need to be implemented to expand Medicaid and limit out-of-pocket 
spending for those with private insurance. Commonwealth goes into detail about the complicated 
process of insulin reaching the user, shown in Figure 9. Manufacturers give rebates to PBMs, or 
Figure 9. Pharmaceutical supply chain of medicine distribution.1 
Pharmacy Benefit Managers, and collect the entire net price of insulin minus those rebates, fees 
paid to wholesalers, and discounts paid to pharmacies. Each of these payments are kept at a 
specific percentage of the overall list price, giving the manufacturers incentive to keep the price 
high, benefiting everyone but the user.  
Ultimately, whether reducing list prices, limiting deductibles, expanding Medicaid, or 
improving health insurance is the solution depends on whether the user has insurance or not. 
While those with Medicaid pay nothing out of pocket, uninsured users pay list prices, unless 
they’re part of manufacturer programs or free clinics, which are rare. Thus, expanding Medicaid 
could be an option to help many low-income users, who often try to use older insulin 
formulations because of lower prices, which are associated with higher risks of hypoglycemic 
episodes, nocturnal hypoglycemia, and increased within-subject variability of blood glucose.1 
For uninsured prescriptions (those without Medicaid), 47% were paid 100% out of pocket and 
only 21% had 0% out-of-pocket cost. Additionally, 71% of uninsured prescriptions were more 
than $100 out of pocket.1 Patients are often uninsured because of low socioeconomic status, and 
these high prescription costs add significant financial stress.  
Those with are privately insured and under 65 pay varying out-of-pocket costs, consisting 
of copayments or an insurer-established price, up to a deductible, plus a coinsurance amount up 
to an out-of-pocket max. Lowering these deductibles and maximums is another strategy, and 
progress has been made here: In Washington State, the Senate bill 6087 issued a state-wide cap 
of $100 per month that began on January 1, 2021.22 This cap has been introduced to several 
western states in the last three years.  
The Affordable Care Act (ACA), enacted in 2010 under the Obama administration, 
required all states to expand Medicaid eligibility to adults with incomes below 138% of the 
federal poverty level.23 The US Supreme Court ruled that expansion could be voluntary for each 
state. In 2014, twenty-nine states expanded Medicaid eligibility, and the effects were observed. 
Many were general improvements, such as easier access to primary care, increased health care 
use, and increase in the number of Medicaid prescriptions. A study done by Myerson, et al. 
aimed to measure the change in different types of Medicaid diabetes prescriptions when the 
eligibility expanded, hoping to see whether the expansion helped lower-income patients with 
diabetes progress to using the newer and better medications.23 As shown in Figure 10, the 
change in Diabetes medications showed significant increase over the period of eligibility 
 
Figure 10. Percent increase in Diabetes medications over expanded Medicaid eligibility. Changes 
recorded as averages over 2014 and 2015, as 29 states expanded in both years. Other non-insulin 


















expansion from 2014 to 2015. Insulin, insulin analogues constituted about a third of the increase 
at 9%, indicating easier access. The last four columns track newer medications and show that as 
much as a third of the increase was likely to newer medications for patients who previously 
lacked insurance and could not pay the high out-of-pocket costs.23 Additionally, the increase in 
prescription fills was significantly higher as patients reached sixty-five, following the trend of 
Diabetes prevalence increasing with age. The exception was an 82% lower increase for people 
65-69 than for people ages 60-64, which was expected, as the older age group is also eligible for 
Medicare, which will be used first. Overall, the study revealed an average of thirty new Medicaid 
prescriptions per 1,000 people in states that expanded eligibility.23 Prescriptions for insulin types 
cumulatively reached nearly a 40% increase after expansions, revealing the greater access when 
the expensive full costs of insulin are covered by Medicaid. Myerson asserts that “gaining 
Medicaid insurance would have significantly reduced out-of-pocket spending for insulin for 
previously uninsured patients, thereby facilitating uptake of the medication.” Expanding 
Medicaid not only saved people money or encouraged use of insulin, but encouraged use of 
newer insulin for lower-income patients.  
Thus, there are several ways to increase insulin accessibility. Allowing generic 
production, regulation of list prices and deductibles for those with insurance, and especially 
expanding Medicaid for those without insurance are all promising ways to cumulatively increase 
access and affordability of insulin and insulin analogues. The focus needs to be on accessibility 
on the newer insulin treatments for those with lower incomes. As insulin remains to be 
imperative for treatment of Diabetes for all patients, we need to address insulin accessibility in 
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